A preliminary treatment study in the 4T1 model with a low dose indicated that ICAM-1-targeted GT DcNP-LFA1-P may provide additional metastatic tumor nodule reduction beyond that of non-targeted GT DcNPs and GT-free drugs. Here, ICAM1 is linked to metastatic neoplasm.